Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix
- Conditions
- Cervical Cancer
- Interventions
- Behavioral: Questionnaires
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT01606293
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01603212
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Preventing Sexual Dysfunction With Aromatase Inhibitors
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Behavioral: QuestionnairesOther: Education MaterialsOther: LuvenaOther: Hyalo-GynOther: Vaginal LubricantBehavioral: Interactive Internet-Based WebsiteBehavioral: Telephone Counseling.
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 187
- Registration Number
- NCT01603303
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Comparison of a Novel 22-gauge Core Biopsy Needle
Not Applicable
Completed
- Conditions
- Malignant Neoplasm of PancreasSolid Pancreatic Mass Lesions
- Interventions
- Device: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT01598194
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Phase 1
Terminated
- Conditions
- LeukemiaLymphoid MalignanciesMetastatic Malignant Neoplasm to the Leptomeninges
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01596127
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Phase 1
Completed
- Conditions
- Advanced CancerSolid Tumor
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01596140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01593020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases
Phase 3
Active, not recruiting
- Conditions
- Metastatic Malignant NeoplasmMetastatic Malignant Neoplasm in the Brain
- Interventions
- Other: Cognitive AssessmentOther: Quality-of-Life AssessmentRadiation: Whole-Brain RadiotherapyRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT01592968
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced Malignant Solid Neoplasm
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT01591356
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase 1
Completed
- Conditions
- Recurrent Hepatosplenic T-Cell LymphomaMycosis FungoidesRecurrent Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Enteropathy-Associated T-Cell Lymphoma
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01590732
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States